April 01, 2024
Migraine-drug maker Impel Pharmaceuticals received confirmation of its Chapter 11 liquidation plan on Monday after selling its assets and making changes to the plan's exculpation provisions in response to a U.S. trustee objection.
February 01, 2024
Migraine-drug maker Impel Pharmaceuticals can proceed with its sale to JN Bidco LLC, which had made a $17.5 million stalking horse bid, U.S. Bankruptcy Judge Stacey G. Jernigan said at a hearing Thursday in a Texas bankruptcy court.
December 20, 2023
Migraine-drug maker Impel Pharmaceuticals Inc. and one of its subsidiaries filed for bankruptcy in Texas, listing $126.9 million in debt and plans to sell itself as a going concern.